MedTrace Logo

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

NCT02590965 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2020-02-13

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial to evaluate the efficacy and safety of Fruquintinib plus best supportive care in patients with advanced non-squamous non-small cell lung cancer who failed to second-line standard chemotherapy.

Conditions

Interventions

DRUG

Fruquintinib

After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.

DRUG

Placebo

Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off

Sponsors & Collaborators

  • Shanghai Chest Hospital

    collaborator OTHER

  • Hutchison Medipharma Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-29
Primary Completion
2015-08-07
Completion
2017-02-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02590965 on ClinicalTrials.gov